Fig. 5: The shedding rate of IDH1.R132H mutant tumors varies among the different subtypes of gliomas.
From: Clinical utility of a blood based assay for the detection of IDH1.R132H-mutant gliomas
a, b MA plots comparing the differential enrichment of (a) IDH1.R132H (Mut) expression and (b) IDH1 wild-type (Wt) expression in matched (n = 24) tumor tissue derived total RNA versus plasma-derived EV RNA. MA plots were created by plotting M value (y-axis; Log2 ratio = Avg. Mut/WT, Plasma/Avg. Mut/WT, Tissue) against A value (x-axis; Average, Mut/Wt tissue and Mut/Wt plasma). a Patients encircled (red circle demonstrated the highest enrichment in plasma. c Scatter-dot plots demonstrating the overall IDH1.R132H MAF% distribution in matched (n = 24) tumor tissue (top) and plasma samples (bottom) across multiple variables (Age, Cortical location, Cerebral hemisphere). Kaplan–Meier survival analysis using IDH1.R132H MAF % cut-off as a prognostic indicator in tumor tissue (c: top, right) and plasma (c: bottom, right). Source Data are provided as a Source Data file.
